{"nctId":"NCT00897104","briefTitle":"MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)","startDateStruct":{"date":"1995-08"},"conditions":["Migraine Headache"],"count":933,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: rizatriptan benzoate (MK0462)"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: sumatriptan"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"rizatriptan benzoate (MK0462)","otherNames":["MK0462"]},{"name":"Comparator: sumatriptan","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participant had at least a 6-month history of migraine, with or without aura\n* Participant was male, or if female, must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions\n* Participant was judged to be in good health, apart from migraine\n\nExclusion Criteria:\n\n* Participant was Pregnant or a nursing mother\n* Participant had a history or current evidence of drug or alcohol abuse\n* Participant had a history or clinical evidence of cardiovascular disease\n* Participant had a clinically significant Electrocardiography (ECG) abnormality\n* Participant had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening\n* Participant had received treatment with an investigational device or compound within 30 days of the study\n* Participant typically suffered from less then 1 or more than 8 attacks of migraine per month\n* Participant had difficulty in distinguishing his/her migraine attacks from tension or interval headaches\n* Participant was currently taking monoamine oxidase inhibitors, methysergide or lithium","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pain Relief at 2 Hours After Treatment","description":"Participants reporting pain relief defined as a reduction of headache severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"223","spread":null},{"groupId":"OG001","value":"238","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"118","spread":null},{"groupId":"OG002","value":"62","spread":null}]}]}]},{"type":"PRIMARY","title":"Time to Relief Within 2 Hours After Treatment","description":"Participants reporting time to relief (defined as the first time that a participant reported grade 0 or 1 in headache severity within 2 hours after treatment (for the comparison of rizatriptan 5 mg and sumatriptan 50 mg).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"247","spread":null},{"groupId":"OG002","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"109","spread":null},{"groupId":"OG002","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Pain Free at 2 Hours After Treatment","description":"Participants pain free (defined as a reduction of headache severity to grade 0 \\[no pain\\]) at 2 hours after treatment. Each participant rated headache severity on a 4-grade scale (0 = no headache; 1 = mild pain; 2 = moderate pain; 3 = severe pain).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"113","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"257","spread":null},{"groupId":"OG001","value":"243","spread":null},{"groupId":"OG002","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Lack of Functional Disability at 2 Hours After Treatment as Measured by the Level of Impairment in Daily Activities","description":"Participants with no functional disability measured by the level of impairment to daily activities at 2 hours after treatment. Each participant rated functional disability on a 4-grade scale (0 =normal; 1 = daily activities mildly impaired; 2 = daily activities severely impaired; 3 =unable to carry out daily activities, required bed rest).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"116","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"148","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"42","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence or Absence of Associated Symptoms (Photophobia, Phonophobia, Nausea, and Vomiting) at 2 Hours After Treatment","description":"Participants who recorded the presence or absence of the associated symptoms photophobia, phonophobia, nausea, and vomiting at 2 hours after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"153","spread":null},{"groupId":"OG002","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"201","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":null},{"groupId":"OG001","value":"125","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"224","spread":null},{"groupId":"OG001","value":"229","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"131","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"221","spread":null},{"groupId":"OG002","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"330","spread":null},{"groupId":"OG002","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Who Used Escape Medication 2 Hours After the Treatment Dose","description":"Escape medication is defined as rescue medication for participants who experienced lack of efficacy from the study medication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73","spread":null},{"groupId":"OG001","value":"55","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"302","spread":null},{"groupId":"OG002","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Relief (Time to Recurrence From the Time of First Recorded Pain Relief [Grade = 0 or 1])","description":"Duration of relief or the time to recurrence from the time of first recorded pain relief (grade = 0 or 1) was calculated for responders who had a headache recurrence","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.07","spread":"6.56"},{"groupId":"OG001","value":"11.58","spread":"5.86"},{"groupId":"OG002","value":"14.38","spread":"5.00"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":355},"commonTop":["Asthenia/Fatigue","Nausea","Dizziness","Somnolence","Paresthesia"]}}}